0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > OX40

OX40

Brief Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:ATC35 Antigen,OX40 Antigen,ACT35,IMD16,OX40,Receptors, OX40,ACT35 antigen,TNFRSF4,CD134,TNF Receptor Superfamily Member 4,TAX Transcriptionally-Activated Glycoprotein 1 Receptor,CD134 Antigen,TXGP1L,Tumor Necrosis Factor Receptor Superfamily, Member 4,Lymphoid Activation Antigene ACT35,OX40 Homologue,Tumor necrosis factor receptor superfamily member 4,Tax-Transcriptionally Activated Glycoprotein 1 Receptor,OX40 Cell Surface Antigen,OX40L receptor
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
OX40 mAb - 01 Lead AutoImmunity Autoimmune disease

Product ListCompare or Buy

Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
CHEK-ATF135 Human Human OX40 (Luc) HEK293 Reporter Cell
EP-162 Human OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit
CHEK-ATP053 Human HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line
OX0-R52H8 Rabbit Rabbit OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-R52H8-structure
OX0-R52H8-sds
OX0-R52H9 Rat Rat OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-R52H9-structure
OX0-R52H9-sds
OX0-C82E9 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His,Avitag™
OX0-C82E9-structure
OX0-C82E9-sds
OX0-M82E5 Mouse Biotinylated Mouse OX40 / TNFRSF4 / CD134 Protein, His,Avitag™
OX0-M82E5-structure
OX0-M82E5-sds
OX0-H5252 Human Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin
OX0-H5252-structure
OX0-H5252-sds
OX0-M522b Marmoset Marmoset OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-M522b-structure
OX0-M522b-sds
TN4-H82E4 Human Biotinylated Human OX40 / TNFRSF4 / CD134 Protein, Avitag™,His Tag (MALS verified) (recommended for biopanning)
TN4-H82E4-structure
TN4-H82E4-sds
OX0-R5253 Rat Rat OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-R5253-structure
OX0-R5253-sds
OX0-H82F7 Human Biotinylated Human OX40 Protein, Fc,Avitag™ (MALS verified)
OX0-H82F7-structure
OX0-H82F7-sds
OX0-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-C5251-structure
OX0-C5251-sds
OX0-C5220 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-C5220-structure
OX0-C5220-sds
OX0-M5259 Mouse Mouse OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-M5259-structure
OX0-M5259-sds
OX0-M5228 Mouse Mouse OX40 / TNFRSF4 / CD134 Protein, His Tag
OX0-M5228-structure
OX0-M5228-sds
OX0-H5224 Human Human OX40 / TNFRSF4 / CD134 Protein, His Tag (MALS verified)
OX0-H5224-structure
OX0-H5224-sds
OX0-H5255 Human Human OX40 / TNFRSF4 / CD134 Protein, Fc Tag
OX0-H5255-structure
OX0-H5255-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATF135-Cell-based assay
 OX40 FACS

Expression analysis of human OX40 on Human OX40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human OX40 (Luc) HEK293 Reporter Cell or negative control cell using biotinylated human OX40 ligand protein followed by staining with Streptavidin-PE.

CHEK-ATP053-Cell-based assay
 OX40 FACS

FACS assay shows that Biotinylated Human OX40 Ligand, Avitag,Fc Tag (OXL-H82F4) can bind to HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line(HEK-ATP053). HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

TN4-H82E4-BLI
 OX40 BLI

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TN4-H82E4-BLI
 OX40 BLI

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rocatinlimab KHK-4083; AMG-451 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd, Amgen Inc Abdominal Pain; Digestive System Diseases; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Autoimmune Diseases; Colitis; Colitis, Ulcerative; Colonic Diseases; Dermatitis, Atopic; Intestinal Diseases Details
Ivuxolimab PF-8600; PF-04518600 Phase 3 Clinical Pfizer Inc Solid tumours; Ovarian Neoplasms; Carcinoma; Carcinoma, Renal Cell; Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
INBRX-106 INBRX-106; ES-102; ES102 Phase 3 Clinical Inhibrx Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Neoplasms; Triple Negative Breast Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
GSK3174998 GSK3174998; GSK 3174998; GSK-3174998 Phase 2 Clinical Glaxosmithkline Plc Neoplasms; Multiple Myeloma Details
Telazorlimab GBR-830; ISB-830 Phase 2 Clinical Glenmark Pharmaceuticals Ltd Dermatitis, Atopic Details
BMS-986178 BMS-986178 Phase 2 Clinical Bristol-Myers Squibb Company Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
SAR-442970 SAR-442970 Phase 2 Clinical Sanofi Inflammation; Hidradenitis Suppurativa Details
IMG-007 IMG-007 Phase 2 Clinical Hutchmed (China) Ltd Alopecia Areata; Dermatitis, Atopic Details
BAT-6026 BAT-6026 Phase 2 Clinical Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd, Bio-Thera Solutions Ltd Solid tumours; Autoimmune Diseases; Dermatitis, Atopic Details
BGB-A445 BGB-A445 Phase 2 Clinical Beigene Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase 1 Clinical Livzon Pharmaceutical Group Inc Neoplasms Details
SL-279252 TAK-252; SL-279252 Phase 1 Clinical Takeda Pharmaceutical Co Ltd, Shattuck Labs Inc Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma Details
FS-120 FS-120 Phase 1 Clinical F-Star Neoplasms; Neoplasm Metastasis Details
Cudarolimab IBI-101 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
ATOR-1015 ADC-1015; ATOR-1015 Phase 1 Clinical Alligator Bioscience Ab Solid tumours; Neoplasms Details
Revdofilimab ABBV-368; PR-1628103 Phase 1 Clinical Abbvie Inc Solid tumours; Head and Neck Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
SHR-1806 SHR-1806 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd Neoplasms Details
Tavolimab MEDI-0562 Phase 1 Clinical Medimmune Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Carcinoma, Squamous Cell; Melanoma Details
Vonlerolizumab RG-7888; MOXR-0916; RO-7021608 Phase 1 Clinical Genentech Inc Neoplasms; Carcinoma, Transitional Cell Details
EMB-09 EMB-09 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Recombinant human anti-OX40 monoclonal antibody (Eucure Biopharma) YH-002 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Solid tumours Details
HFB-3010(HiFiBiO Therapeutics) HFB-3010; HFB-301001 Phase 1 Clinical HiFiBiO Therapeutics Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Sarcoma; Uterine Neoplasms; Carcinoma, Hepatocellular; Melanoma Details
HLX-51 HLX-51 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Lymphoma Details
KN-052 KN-052 Phase 1 Clinical Suzhou Alphamab Co Ltd Solid tumours Details
MEDI-6469 MEDI-6469; AGX-051 Phase 1 Clinical Providence Cancer Center, AgonOx Inc, Astrazeneca Plc, Providence Health & Services Liver Neoplasms; Head and Neck Neoplasms; Solid tumours; Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken